INCANNEX HEALTHCARE INC (IXHL) Stock Price & Overview
NASDAQ:IXHL • US45333F2083
Current stock price
The current stock price of IXHL is 3.045 USD. Today IXHL is down by -6.02%. In the past month the price decreased by -23.58%. In the past year, price decreased by -84.57%.
IXHL Key Statistics
- Market Cap
- 42.539M
- P/E
- N/A
- Fwd P/E
- 2.35
- EPS (TTM)
- -255.48
- Dividend Yield
- N/A
IXHL Stock Performance
IXHL Stock Chart
IXHL Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to IXHL. When comparing the yearly performance of all stocks, IXHL is a bad performer in the overall market: 98.75% of all stocks are doing better.
IXHL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to IXHL. While IXHL has a great health rating, there are worries on its profitability.
IXHL Earnings
IXHL Forecast & Estimates
For the next year, analysts expect an EPS growth of 99.78% and a revenue growth -100% for IXHL
IXHL Groups
Sector & Classification
IXHL Financial Highlights
Over the last trailing twelve months IXHL reported a non-GAAP Earnings per Share(EPS) of -255.48. The EPS increased by 55.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.66% | ||
| ROE | -66.07% | ||
| Debt/Equity | 0 |
IXHL Ownership
IXHL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.51 | 828.496B | ||
| JNJ | JOHNSON & JOHNSON | 20.82 | 579.15B | ||
| MRK | MERCK & CO. INC. | 23.1 | 295.772B | ||
| PFE | PFIZER INC | 9.18 | 153.813B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.44 | 119.215B | ||
| ZTS | ZOETIS INC | 16.22 | 47.848B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9 | 26.738B | ||
| VTRS | VIATRIS INC | 5.21 | 15.026B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.38 | 11.5B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.997B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.705B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.62B | ||
| CORT | CORCEPT THERAPEUTICS INC | 45.45 | 4B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IXHL
Company Profile
Incannex Healthcare Inc is a AU-based company operating in Pharmaceuticals industry. Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
Company Info
IPO: 2022-03-18
INCANNEX HEALTHCARE INC
8 Century Circuit, Ste. 105, Norwest
New York City NEW SOUTH WALES AU
Employees: 12
Phone: 18004831140
INCANNEX HEALTHCARE INC / IXHL FAQ
What does INCANNEX HEALTHCARE INC do?
Incannex Healthcare Inc is a AU-based company operating in Pharmaceuticals industry. Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
Can you provide the latest stock price for INCANNEX HEALTHCARE INC?
The current stock price of IXHL is 3.045 USD. The price decreased by -6.02% in the last trading session.
Does IXHL stock pay dividends?
IXHL does not pay a dividend.
What is the ChartMill rating of INCANNEX HEALTHCARE INC stock?
IXHL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of INCANNEX HEALTHCARE INC (IXHL) based on its PE ratio?
INCANNEX HEALTHCARE INC (IXHL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-255.48).
Should I buy IXHL stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IXHL.
Can you provide the upcoming earnings date for INCANNEX HEALTHCARE INC?
INCANNEX HEALTHCARE INC (IXHL) will report earnings on 2026-05-13.